ArticleThe journal of nutrition, health & aging2025
Accelerated pace of frailty in patients with schizophrenia.
Article in The journal of nutrition, health & aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aging in Schizophrenia: Clinical, Biological, and Psychosocial Perspectives.Geriatrics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia is associated with an increased risk of mortality and physical comorbidities, indicating a potentially accelerated frailty process in affected individuals. This study aimed to test association between schizophrenia and frailty using the frailty index based on laboratory markers (FI-Lab).
methodsA total of 600 patients with schizophrenia and 518 healthy controls, aged between 20 and 69 years were included in the present study. Frailty was assessed using the FI-Lab, incorporating routine laboratory markers, body mass index, and blood pressure measurements. FI-Lab for patients with schizophrenia and healthy controls was compared, with stratification by age group and sex. In addition, robust was defined as FI-Lab ≤ 0.12, pre-frail as 0.12-0.25, and frail as >0.25. Multiple linear regression analysis was used to test the association between schizophrenia and FI-Lab. Multinomial logistic regression was used to test the association between schizophrenia and frailty status. Spearman correlation analysis was performed to assess the relationship between the Positive and Negative Syndrome Scale (PANSS) scores and FI-Lab in schizophrenia patients.
resultsSchizophrenia patients exhibited significantly higher FI-Lab than healthy controls across all age groups, indicating accelerated pace of frailty in schizophrenia patients. Schizophrenia was significantly associated with FI-Lab (β = 0.044, p = 0.004) in the adjusted model. Schizophrenia was significantly associated with both pre-frail status (OR = 2.26, 95% CI = 1.40-3.68, p = 0.001) and frail status (OR = 10.33, 95% CI = 5.65-19.93, p = 0.007) compared to robust status in the adjusted model. Additionally, a positive correlation between FI-Lab and PANSS scores suggests that more severe schizophrenia symptoms correlate with higher degree of frailty.
conclusionThese findings suggest that schizophrenia contributes to an increased risk of frailty. The FI-Lab provides a quantitative measure of frailty. This underscores the importance of integrating frailty considerations into the treatment and management of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.